Medicare CBD access: Michigan’s hemp industry is watching a new CMS pilot that lets certain Medicare beneficiaries receive qualifying hemp-derived products (up to $500 annually) through participating health-care organizations—raising fresh questions about how state rules could decide which companies benefit. CBD/THC policy pressure: The federal hemp ban debate keeps heating up, with lawmakers and courts weighing how THC products should be handled as states and companies position for what comes next. Clinical cannabis research: A new report highlights a plant-derived cannabis preparation as safe and effective for children with autism, adding to the growing clinical conversation around cannabinoid-based treatments. Public health & youth vaping: Metro health experts urge parents to talk early about vaping before school starts, warning that nicotine and other inhaled substances can harm lungs and brain development—an issue that often overlaps with broader cannabis use concerns. Legal system ripple effects: A high-profile murder trial in New York will use an anonymous jury, showing how intense publicity can shape court procedures—while other cases continue to involve cannabis in drug-driving and possession allegations. Industry business moves: Aurora Cannabis responded to Curaleaf’s unsolicited takeover bid, underscoring how consolidation and regulation uncertainty are colliding in medical cannabis markets.